Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
25 hedge funds and large institutions have $24.4M invested in Catalyst Pharmaceutical in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
227% more capital inflows, than outflows
Capital inflows: $5.75M | Capital outflows: $1.76M
56% more funds holding
Funds holding: 16 → 25 (+9)
1.15% more ownership
Funds ownership: 13.63% → 14.78% (+1.2%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$3.19M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
| 3 |
EAM Investors
Solana Beach,
California
|
+$752K |
| 4 |
Renaissance Technologies
New York
|
+$233K |
| 5 |
Bank of New York Mellon
New York
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.26M |
| 2 |
Sophrosyne Capital
New York
|
-$455K |
| 3 |
UBS
Zurich,
Switzerland
|
-$16K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 5 |
Credit Suisse
Zurich,
Switzerland
|
-$12K |
CPRX Hedge Fund Activity: Q3 2013 in Review
25 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2013, worth a combined $24.4M — up 387% from $5.01M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CPRX positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $3.19M. The largest seller was Federated Hermes, cutting an estimated $1.26M.
- 25 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2013, up from 16 in Q2 2013.
- Funds reported $24.4M of Catalyst Pharmaceutical stock for Q3 2013, up 387% quarter-over-quarter.
- 12 funds opened new Catalyst Pharmaceutical positions in Q3 2013 and 3 closed out, a net change of +9 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2013 was OrbiMed, an estimated $3.19M added.
- The largest Catalyst Pharmaceutical seller in Q3 2013 was Federated Hermes, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2013.